Loop Capital raised the firm’s price target on Tempus AI (TEM) to $74 from $52 and keeps a Buy rating on the shares. The company’s Q4 results were consistent with its pre-announcement, and the firm maintains its belief that Tempus is a play on the precision medicine trends sweeping through health care, the analyst tells investors in a research note. Tempus AI should remain a long-term beneficiary of next-generation sequencing, which is at a tipping point as it rapidly becomes the standard of care, Loop added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Buy Rating for Tempus AI, Inc. Amid Strong Growth Prospects and Strategic Acquisition
- Tempus AI, Inc.: Hold Rating Amid Balanced Long-Term Potential and Current Valuation Concerns
- Tempus AI downgraded to Neutral from Overweight at JPMorgan
- Tempus AI, Inc.: Promising Growth Prospects and Strategic Initiatives Support Buy Rating
- Closing Bell Movers: Hims & Hers down nearly 20% on earnings miss